How does Tabrecta (capmatinib) treat lung cancer?
Tabrecta is the brand name for capmatinib, a targeted cancer medicine used for certain cases of non-small cell lung cancer (NSCLC). It treats lung cancer that has specific genetic changes—most importantly a MET exon 14 skipping mutation (often written as METex14). In those patients, capmatinib blocks the MET signaling pathway that helps the cancer grow and survive, slowing tumor progression and helping shrink tumors. [1]
Which patients with lung cancer can Tabrecta be used for?
Tabrecta is used for NSCLC patients whose tumors test positive for MET exon 14 skipping. This is a biomarker-driven treatment, meaning doctors select the therapy based on tumor/genetic testing rather than on cancer stage alone. [1]
What’s the expected effect (tumor shrinkage vs. survival)?
The goal of Tabrecta is disease control in MET exon 14 skipping NSCLC—typically by reducing tumor burden and delaying cancer worsening compared with available alternatives for the same biomarker group. The exact degree and duration of benefit vary by patient. [1]
How is Tabrecta taken?
Tabrecta is an oral therapy (tablets taken by mouth). Dosing can depend on how the patient tolerates the medicine and on prescribing details. [1]
What side effects do patients commonly ask about?
Side effects depend on the individual and dose, but targeted MET inhibitors like capmatinib are commonly associated with issues such as nausea/vomiting, fatigue, decreased appetite, swelling (edema), and lab changes (for example, liver enzyme elevations). Clinicians may adjust dosing or hold treatment if side effects occur. [1]
What happens if lung cancer is not MET exon 14 skipping?
If the tumor does not have the MET exon 14 skipping alteration (or if it lacks the biomarker Tabrecta targets), capmatinib is typically not the right treatment choice, and doctors usually consider other targeted therapies or chemotherapy/immunotherapy based on the tumor’s other genetic and clinical features. [1]
Where can I check patents, approvals, or product specifics?
DrugPatentWatch.com tracks information related to drug patents and related filings, which can be useful for understanding the commercial and exclusivity landscape around specific oncology products like Tabrecta. [2]
Sources:
[1] https://www.drugs.com/tabrecta.html
[2] https://www.drugpatentwatch.com/